Phase II Study of AZD 2171 in Patients With Recurrent Small Cell Lung Cancer.

Trial Profile

Phase II Study of AZD 2171 in Patients With Recurrent Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Cediranib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2010 Planned end date (1 Mar 2010) added as reported by ClinicalTrials.gov.
    • 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 18 May 2008 Status changed from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top